Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1

Xenobiotica

Volumn 35, Issue 12, 2005, Pages 1101-1119

  Miksits, M ^a   Maier Salamon, A ^a   Aust, S ^b   Thalhammer, T ^b   Reznicek, G ^a   Kunert, O ^c   Haslinger, E ^c   Szekeres, T ^b   Jaeger, W ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Human liver; Resveratrol; Sulfation; SULT1A1; SULT1E1

Indexed keywords

RECOMBINANT ENZYME; RECOMBINANT SULFOTRANSFERASE 1A1; RECOMBINANT SULFOTRANSFERASE 1A2; RECOMBINANT SULFOTRANSFERASE 1A3; RECOMBINANT SULFOTRANSFERASE 1E1; RESVERATROL; RESVERATROL 3 O 4' O DISULFATE; RESVERATROL 3 O SULFATE; RESVERATROL 4' O SULFATE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; DRUG SULFATION; DRUG UPTAKE; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER CYTOSOL; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SIGMOID;

ADOLESCENT; ADULT; AGED; ARYLSULFOTRANSFERASE; CHROMATOGRAPHY, LIQUID; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; KINETICS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; STILBENES; SULFATES; SULFOTRANSFERASES;

VITACEAE;

EID: 31544471832     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500354253     Document Type: Article

References (48)

1. Andlauer W, Kolb J, Siebert K, Furst P. 2000. Assessment of resveratrol bioavailability in the perfused small intestine of the rat, Drugs under Experimental and Clinical Research 26:47-55.
2. Anderson RJ, Kudlacek PE, Clemens DL. 1998. Sulfation of minoxidil by multiple human cytosolic sulfotransferases, Chemico-Biological Interations 109:53-67.
3. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J, Sabolovic N. 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human, Archives of Biochemistry and Biophysics 393:281-289.
4. Banoglu E. 2000. Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens, Current Drug Metabolism 1:1-30.
5. Bertelli AAE, Giovannini L, Gianessi D, Migliori M, Bernini W, Fregoni M, Bertelli A. 1995. Antiplatelet activity of synthetic and natural Resveratrol in red wine, International Journal of Tissue Reactions 17:1-3.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry 72:248-254.
7. Chen CK, Pace-Asciak CR. 1996. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta, General Pharmacology 27:363-366.
8. Constant J. 1997. Alcohol, ischemic heart disease, and the French paradox, Coronary Artery Disease 8:645-649.
9. Debella A, Haslinger E, Kunert O, Michl G, Abebe D. 1999. Steroidal saponins from Asparagus africanus, Phytochemistry 51:1069-1075.
10. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000a. Sulphation of resveratrol, a natural compound present in grapes and wine, in the human liver and duodenum, Xenobiotica 30:609-617.
11. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000b. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids, Xenobiotica 30:857-866.
12. Dickinson RG, King AR, Kelly MA, Kaltashov IA, Fenselau C. 1994. Excretion of 3-hydroxy-diflunisal as a monosulphate conjugate - identification using ESI-MS, Journal of Pharmaceutical Biomedical Analysis 12:1075-1078.
13. Dooley TP, Haldeman-Cahill R, Joiner J, Wiborn TW. 2000. Expression profiling of human sulfotransferase and sulfatase gene superfamilies in epithelial tissues and cultured cells, Biochemical and Biophysical Research Communications 277:236-245.
14. Falany CN, Wheeler J, Oh TS, Falany JL. 1994. Steroid sulfation by expressed human cytosolic sulfotransferases, Journal of Steroid Biochemistry and Molecular Biology 48:369-375.
15. Frémont L, Belguendouz L, Delpal S. 1999. Annoxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids, Life Sciences 64:2511-2521.
16. Frémont L. 2000. Biological effects of resveratrol, Life Sciences 66:663-673.
17. Garay RP, Rosati C, Fanous K, Allard M, Morin E, Lamiable D, Vistelle R. 1995. Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat, European Journal of Pharmacology 274:175-180.
18. Gehm BD, Mcandrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proceedings of the National Academy of Sciences, USA 94:14138-14143.
19. Gescher AJ, Steward WP. 2003. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum, Cancer Epidemiology Biomarkers and Prevention 12:953-957.
20. Glatt H. 2000. Sulfotransferases in the bioactivation of xenobiotics, Chemico-Biological Interactions 129:141-170.
21. Glatt M. 2002. Sulphotransferases. In: Ioannides C, editor, Enzyme systems that metabolise drugs and other xenobiotics. Chichester: Wiley, pp 353-439.
22. Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. 2005. Synergistic action of resveratrol, an ingredient of wine, with Arc-C and tiazofurin in HL-60 human promyelocytic leukemia cells, Experimental Hematology 33:329-335.
23. Hutzler JM, Tracy TS. 2002. Atypical kinetic profiles in drug metabolism reactions, Drug Metabolism and Disposition 30:355-362.
24. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science 275:218-220.
25. Kaldas MI, Walle UK, Walle T. 2003. Resveratrol transport and metabolism by human intestinal Caco-2 cells, Journal of Pharmacy and Pharmacology 55:307-312.
26. Kim HJ, Cho JH, Klaassen CD. 1995. Depletion of hepatic 3′-phosphoadenosine 5′-phosphosulfate (PAPS) and sulfate in rats by xenobiotics that are sulfated, Journal of Pharmacology and Experimental Therapeutics 275:654-658.
27. Leilich G, Knauf H, Mutschler E, Volger KD. 1980. Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application, Arzneimittelforschung 30:949-953.
28. Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. 2003. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses, Biochemical and Biophysical Research Communications 309:1017-1026.
29. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidence by a linked-rat model, Journal of Pharmacology and Experimental Therapeutics 302:369-373.
30. Meng X, Maliakal P, Lu H, Lee MJ, Yang CS. 2004. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice, Journal of Agricultural and Food Chemistry 52:935-942.
31. Morris ME, Hansel SB. 1990. High-performance liquid chromatographic analysis of p-nitrophenol and its conjugates in biological samples, Journal of Chromatography B 532:285-293.
32. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jäger W. 2004. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship, Bioorganic and Medicinal Chemistry 12:5571-5578.
33. Murias M, Jaeger W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L. 2005. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship, Biochemical Pharmacology 69:903-912.
34. Nakano H, Ogura K, Takahashi E, Harada T, Nishiyama T, Muro K, Hiratsuka A, Kadota S, Watabe T. 2004. Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases, Drug Metabolism and Pharmacokinetics 19:216-226.
35. Nowell S, Green B, Tang YM, Wiese R, Kadlubar FF. 2005. Examination of human tissue cytosols for expression of sulfotransferase isoform 1A2 (SULT1A2) using a SULT1A2-specific antibody, Molecular Pharmacology 67:394-399.
36. Pasqualini JR, Chetrite GS. 2005. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer, Journal of Steroid Biochemistry and Molecular Biology 93:221-236.
37. Raftogianis RB, Wood TC, Weinshilboum RM. 1999. Human phenol sulfotransferases SULT1A2 and SULT1A1. Genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations, Biochemical Pharmacology 58:605-616.
38. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtire MW. 2001. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain, Journal of Clinical Endocrinology and Metabolsim 86:2734-2742.
39. Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, Coughtrie MW. 2003. Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models, Drug Metabolism and Disposition 31:1187-1197.
40. Thomas NL, Coughtrie MW. 2003. Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1, Xenobiotica 33:1139-1148.
41. Tsan MF, White JE, Maheshwari JG, Chikkappa G. 2002. Anti-leukemia effect of resveratrol, Leukemia and Lymphoma 43:983-987.
42. Urpi-Sarda M, Jauregui O, Lamuela-Raventos RM, Jaeger W, Miksits M, Covas MI, Andres-Lacueva C. 2005. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry, Analytical Chemistry 77:3149-3155.
43. Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. 2002. The in vivo human metabolism of tibolone, Drug Metabolism and Disposition 30:106-112.
44. Walle T, Hsieh F, Delegge MH, Oatis JE, Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans, Drug Metabolism and Disposition 32:1377-1382.
45. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. 2001. Mechanisms of cardioprotection by resveratrol, a phenolic antioxidant present in red wine, International Journal of Molecular Medicine 8:3-17.
46. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, Van Breeman RB. 2002. Human, rat, and mouse metabolism of resveratrol, Pharmaceutical Research 19:1907-1914.
47. Zou JG, Huang YZ, Chen Q, Wei EH, Hsieh TC, Wu JM. 1999. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein, IUBMB Life 47:1089-1096.
48. Zuckerman A, Bolan E, De Paulis T, Schmidt D, Spector S, Pasternak GW. 1999. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate, Brain Research 842:1-5.